Journal of Experimental & Clinical Cancer Research
Overcoming immune checkpoint inhibitor-mediated T-cell exhaustion with a TCR β chain-directed selective dual T-cell activator
Abstract Background Resistance to immune checkpoint inhibition (ICI) using antibodies against the PD-1/PD-L1 axis remains a significant clinical challenge. Here, we report that combination of anti-PD-1 with a bifunctional fusion molecule, anti-TCRβ-IL-2, comprised of a monovalent Fab that binds and activates the T-cell receptor (TCR) through distinct variable beta (Vβ) chain residues and an IL-2 molecule, mediates robust anti-tumor control in the context of ICI resistance. Methods Syngeneic murine models with varyi …